Showing results (71-80 of 86) with videos related to
Sort By:
Pageof 9
RMD Open|January 12, 2024
Frequency of irritable bowel syndrome in spondyloarthritis: a multicentric cross-sectional study and meta-analysisJessika Bernard, Thomas Barnetche, Charlotte Amory, et al.Journal of the American Academy of Dermatology|August 10, 2018
Association of skin hyperpigmentation disorders with digital ulcers in systemic sclerosis: Analysis of a cohort of 239 patientsVaianu Leroy, Pauline Henrot, Thomas Barnetche, et al.Journal of the American Academy of Dermatology|June 10, 2015
Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysisAxel Patrice Villani, Marie Rouzaud, Morgane Sevrain, et al.Arthritis & Rheumatology (Hoboken, N.J.)|March 19, 2016
IgE Inhibits Toll-like Receptor 7- and Toll-like Receptor 9-Mediated Expression of Interferon-α by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus ErythematosusLiliane Khoryati, Jean-François Augusto, Emilie Shipley, et al.Journal of Clinical Medicine|May 15, 2019
Intestinal Inflammation in Children with Cystic Fibrosis Is Associated with Crohn's-Like Microbiota DisturbancesRaphaël Enaud, Katarzyna B Hooks, Aurélien Barre, et al.ACR Open Rheumatology|February 18, 2025
Chronicity of Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis After Immunotherapy Discontinuation: Results From the Canadian Research Group of Rheumatology in Immuno-Oncology DatabaseAlexandra Ladouceur, Shahin Jamal, Alexandra Saltman, et al.RMD Open|November 21, 2024
Impact of autoantibody status on stratifying the risk of organ involvement and mortality in SSc: experience from a multicentre French cohort of 1605 patientsKevin Didier, Vincent Sobanski, Ailsa Robbins, et al.Joint Bone Spine|October 24, 2024
Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational studyAlexandra Ladouceur, Thomas Barnetche, Sorilla Prey, et al.European Journal of Cancer (Oxford, England : 1990)|October 14, 2021
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse eventsMarie Kostine, Eleonora Mauric, Alice Tison, et al.Annals of the Rheumatic Diseases|November 18, 2017
Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort studyMarie Kostine, Léa Rouxel, Thomas Barnetche, et al.Pageof 9